Press releases
-
Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress
-Four abstracts, including two oral and two poster presentations, highlight Ferring’s dedication and multi-focus approach to advancing fertility care Parsippany, NJ – October 18, 2024 – Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually. “We are pleased to share […]
-
Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
-New outcomes analyses evaluated efficacy and safety of REBYOTA in patients with recurrent C. diff infection in a real-world setting Patients were followed after receiving REBYOTA at home or in a clinic Findings add to the growing body of real-world evidence for REBYOTA Parsippany, NJ – October 16, 2024 – Ferring Pharmaceuticals today announced the presentation of two data analyses […]
-
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
-A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in trials conducted in the U.S. and Japan Pivotal U.S. Phase 3 study results published in The Spine Journal About nine million adults in the U.S. suffer from lumbar disc herniation each year Parsippany, NJ – September 25, 2024 – Ferring Pharmaceuticals […]